DK0490972T4 - Ekspressionssystemer for rekombinante negativstreng-RNA-vira og vacciner - Google Patents

Ekspressionssystemer for rekombinante negativstreng-RNA-vira og vacciner

Info

Publication number
DK0490972T4
DK0490972T4 DK90913914T DK90913914T DK0490972T4 DK 0490972 T4 DK0490972 T4 DK 0490972T4 DK 90913914 T DK90913914 T DK 90913914T DK 90913914 T DK90913914 T DK 90913914T DK 0490972 T4 DK0490972 T4 DK 0490972T4
Authority
DK
Denmark
Prior art keywords
rna
copied
templates
viral
influenza
Prior art date
Application number
DK90913914T
Other languages
Danish (da)
English (en)
Other versions
DK0490972T3 (da
Inventor
Peter Palese
Mark Krystal
Jeffrey D Parvin
Original Assignee
Medimmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0490972(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Vaccines Inc filed Critical Medimmune Vaccines Inc
Publication of DK0490972T3 publication Critical patent/DK0490972T3/da
Application granted granted Critical
Publication of DK0490972T4 publication Critical patent/DK0490972T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90913914T 1989-08-28 1990-08-27 Ekspressionssystemer for rekombinante negativstreng-RNA-vira og vacciner DK0490972T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39972889A 1989-08-28 1989-08-28
US44005389A 1989-11-21 1989-11-21
US07/527,237 US5166057A (en) 1989-08-28 1990-05-22 Recombinant negative strand rna virus expression-systems

Publications (2)

Publication Number Publication Date
DK0490972T3 DK0490972T3 (da) 1995-10-30
DK0490972T4 true DK0490972T4 (da) 2007-01-08

Family

ID=27410354

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90913914T DK0490972T4 (da) 1989-08-28 1990-08-27 Ekspressionssystemer for rekombinante negativstreng-RNA-vira og vacciner

Country Status (13)

Country Link
US (2) US5166057A (de)
EP (1) EP0490972B2 (de)
JP (1) JP3293620B2 (de)
AT (1) ATE126272T1 (de)
AU (1) AU636916B2 (de)
CA (1) CA2065245C (de)
DE (5) DE69021575T4 (de)
DK (1) DK0490972T4 (de)
ES (1) ES2075901T5 (de)
GR (1) GR900100639A (de)
NL (4) NL300341I1 (de)
PT (1) PT95124B (de)
WO (1) WO1991003552A1 (de)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US20060019350A1 (en) * 1989-08-28 2006-01-26 Peter Palese Recombinant negative strand RNA virus expression system and vacccines
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6887699B1 (en) * 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
HUT69956A (en) * 1990-08-14 1995-09-28 Isis Pharmaceuticals Inc Methode for inhibition of influenza virus by antiseuse oligonucleotides
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
US7374768B1 (en) * 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
EP0492920A1 (de) * 1990-12-24 1992-07-01 Merck & Co. Inc. Chimärer Influenza-HIV Impfstoff
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
ES2247584T3 (es) * 1992-04-14 2006-03-01 The Mount Sinai School Of Medicine Of The City University Of New York Virus atenuados por ingenieria genetica.
WO1994013837A1 (en) * 1992-12-07 1994-06-23 Lionel Resnick Method for detecting a virus
AU7104194A (en) * 1993-06-11 1995-01-03 Peter Palese High yielding influenza viruses
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
AU2359195A (en) * 1994-04-19 1995-11-10 Thomas Jefferson University Viral ribonucleocapsid as an immunological enhancer
AU682968B2 (en) * 1994-05-20 1997-10-23 Mount Sinai School Of Medicine Of The City University Of New York, The Treatment of influenza virus infection using antivirals that inhibit acylation/palmitylation of hemagglutinin
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5597697A (en) * 1994-09-30 1997-01-28 Diamond; Paul Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases
US7465574B2 (en) * 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
EP0704533A1 (de) * 1994-09-30 1996-04-03 Bayer Ag Abgeschwächtes Impfvirus, Verfahren zur dessen Herstellung und Arzneimittel die es enthalten
AU3760495A (en) * 1994-09-30 1996-04-26 Aviron Chimeric Influenza Virus And Electroporation Method
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5698433A (en) * 1994-11-10 1997-12-16 Immuno Ag Method for producing influenza virus and vaccine
DE19503082A1 (de) * 1995-02-01 1996-08-08 Univ Ludwigs Albert Gegenstand und Verfahren zur bevorzugt transienten Expression und möglichen Translation spezifischer RNA im cytoplasmatischen Bereich höherer eukaryontischer Zellen
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DK0780475T4 (da) * 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus
KR100754091B1 (ko) 1995-10-31 2007-08-31 가부시끼가이샤 디나벡 겡뀨쇼 자율 복제 능력을 갖는 (-)쇄 ｒｎａ 바이러스 벡터
CA2236378C (en) * 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
ES2109189B1 (es) * 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
JP2000509280A (ja) * 1996-05-01 2000-07-25 アメリカ合衆国 組換えｄｎａ由来ヌクレオキャプシドタンパク質を用いるウイルストランスフェクタントの作製
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
EP2298900A1 (de) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US20030125280A1 (en) * 1996-12-03 2003-07-03 Medical University Of South Carolina Tissue specific and target RNA-specific ribozymes as antimicrobial therapeutics against microbial pathogens
US6884414B1 (en) * 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
WO1998050405A1 (en) 1997-05-07 1998-11-12 Cleveland Clinic Foundation An infectious clone for human parainfluenza virus type 3
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6872518B2 (en) * 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US6830748B1 (en) 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
EP1900818A3 (de) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neissersche Antigene
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
PT1056884E (pt) 1998-02-27 2002-06-28 Pamgene Bv Processo para a amplificacao nao especifica de acido nucleico
JP2002509729A (ja) * 1998-03-27 2002-04-02 サイトス バイオテクノロジー アーゲー 誘導性のアルファウイルス遺伝子発現系
EP2261343A3 (de) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
ES2301241T3 (es) 1998-06-12 2008-06-16 Mount Sinai School Of Medicine Of The City University Of New York Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen.
JP4531255B2 (ja) 1998-06-12 2010-08-25 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー ワクチンおよび医薬として使用される、改変されたインターフェロン拮抗活性を有する弱毒（−）鎖ウイルス
WO1999067400A1 (en) * 1998-06-24 1999-12-29 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
WO2000006205A1 (en) 1998-07-29 2000-02-10 Invitrogen Corporation Regulated expression of recombinant proteins using rna viruses
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US7326542B2 (en) * 1998-12-02 2008-02-05 Princeton University Compositions and methods for regulating bacterial pathogenesis
US6720415B2 (en) * 1998-12-02 2004-04-13 Princeton University Compositions and methods for regulating bacterial pathogenesis
EP1035209A1 (de) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stabile rekombinante Influenzaviren, die frei von Helfervirus sind
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
AU778737B2 (en) * 1999-04-14 2004-12-16 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DK1228217T3 (da) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CN1451038A (zh) * 1999-07-30 2003-10-22 埃西斯创新有限公司 可用作疫苗的减毒流感病毒
ES2543736T3 (es) 1999-10-29 2015-08-21 Glaxosmithkline Biologicals Sa Péptidos antigénicos de Neisseria
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US20030194696A1 (en) * 2000-03-28 2003-10-16 University Of Rochester Methods of producing a library and methods of selecting polynucleotides of interest
CA2405499A1 (en) * 2000-03-28 2001-10-04 Maurice Zauderer Methods of producing a library and methods of selecting polynucletides
US6635416B2 (en) * 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
CA2406100C (en) 2000-04-28 2010-11-02 St. Jude Children's Research Hospital Dna transfection system for the generation of infectious influenza virus
EP1299819A2 (de) * 2000-05-12 2003-04-09 Cyril John Higgins Methode des organisierten wiederauffindens von seiten im world wide web
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
CN1455816A (zh) * 2000-06-23 2003-11-12 美国氰胺公司 从cDNA中挽救犬热病病毒
AU2001273432A1 (en) * 2000-07-13 2002-01-30 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
WO2002046449A2 (en) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection of catalytic nucleic acids targeted to infectious agents
WO2002098457A2 (en) * 2001-01-17 2002-12-12 Thomas Jefferson University Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US8927206B2 (en) 2001-01-19 2015-01-06 Vironovative B.V. Virus causing respiratory tract illness in susceptible mammals
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002309133A1 (en) 2001-04-17 2002-10-28 Institut Pasteur Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
ES2563402T3 (es) * 2002-02-13 2016-03-15 Wisconsin Alumni Research Foundation Señal para el empaquetamiento de vectores del virus de la gripe
KR101011410B1 (ko) * 2002-02-13 2011-01-28 위스콘신 얼럼나이 리서어치 화운데이션 인플루엔자 바이러스 벡터의 패키징을 위한 신호
EP1485488A4 (de) * 2002-02-21 2005-03-02 Sinai School Medicine Rekombinante expressionssysteme für minusstrang-virus-rna und impfstoffe
MXPA04008088A (es) 2002-02-21 2005-09-30 Medimmune Vaccines Inc Sistema de expresion del virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metapneumovirus.
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP1572108A4 (de) * 2002-09-27 2008-09-17 Medimmune Vaccines Inc Funktionale mutationen des rsv (respiratory syncytial virus)
US20070224124A1 (en) * 2002-09-30 2007-09-27 University Of South Florida Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
KR101187955B1 (ko) * 2003-04-25 2012-10-08 비로노바티브 비브이 메타뉴모바이러스 유래 이종 항원을 포함하는 재조합파라인플루엔자 바이러스 발현 시스템 및 백신
EP2494986A1 (de) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirusstämme und deren Verwendung in Impfstoffformulierungen und als Vektoren für die Expression antigener Sequenzen und Verfahren zur Ausbreitung des Virus
CN1826407B (zh) * 2003-05-28 2013-09-11 威斯康星旧生研究基金会 用于疫苗和基因治疗的高滴度重组流感病毒
EP2581093B1 (de) * 2003-06-16 2015-03-18 MedImmune, LLC Influenza-Hämagglutinin- und Neuraminidase-Varianten
CA2530956A1 (en) * 2003-07-03 2005-03-03 Board Of Trustees Operating Michigan State University Expression of a recombinant transgene
EP2311994A1 (de) * 2003-08-01 2011-04-20 Life Technologies Corporation Zusammensetzungen und Verfahren zur Aufreinigung kurzer RNA-Moleküle und anderer Nukleinsäuren
US7807646B1 (en) * 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
DE602004027537D1 (de) * 2003-12-23 2010-07-15 Medimmune Inc
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
KR101222281B1 (ko) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
AU2005248377B2 (en) * 2004-05-25 2011-03-24 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2497492B1 (de) 2004-06-01 2018-08-08 Icahn School of Medicine at Mount Sinai Genetisch veränderter Schweineinfluenzavirus und Verwendungen damit
CA2587451A1 (en) 2004-11-11 2006-05-18 Solvay Pharmaceuticals B.V. Defective influenza virus particles
JP2008520248A (ja) 2004-11-19 2008-06-19 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション タンデム転写ユニットを有する組換えインフルエンザベクター
AU2011204881B2 (en) * 2004-12-24 2012-04-19 Abbott Biologicals B.V. Rescue of influenza virus
AU2005318087B2 (en) * 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
EP1855713B1 (de) * 2005-02-15 2016-04-27 Mount Sinai School of Medicine Gentechnisch hergestellter pferde-influenza-virus und seine verwendungen
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US20060216700A1 (en) * 2005-03-10 2006-09-28 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2006110214A2 (en) * 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
EP2573114B1 (de) 2005-08-10 2016-03-30 MacroGenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden Fc-Regionen und Anwendungsverfahren dafür
US9119810B2 (en) * 2005-11-18 2015-09-01 Rutgers, The State University Of New Jersey Compositions and vaccines against influenza A and influenza B infections
MY147379A (en) 2005-12-02 2012-11-30 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
MX2008013388A (es) 2006-04-19 2009-03-02 Medimmune Llc Metodos y composiciones para expresar arn viral en sentido negativo en celulas caninas.
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US7507411B2 (en) * 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
US7601356B2 (en) * 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
WO2008021959A2 (en) * 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2473275T3 (es) 2006-09-15 2014-07-04 Medimmune, Llc Líneas de células MDCK que soportan el crecimiento viral hasta altos títulos y proceso de biorreactor que las usa.
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
US8597661B2 (en) * 2007-05-04 2013-12-03 Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2069484B1 (de) * 2007-06-18 2014-08-13 MedImmune, LLC Influenza-B-Viruses mit verändertem Hämagglutininpolypeptid
EP2158221B1 (de) 2007-06-21 2018-08-29 MacroGenics, Inc. Kovalente diabodies und deren verwendung
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
MX2011000437A (es) 2008-07-11 2012-03-07 Medimmune Llc Variantes de hemaglutinina y neuramnidasa de influenza.
EP2334328A4 (de) 2008-09-24 2012-08-29 Medimmune Llc Verfahren zur reinigung von viren
HUE043084T2 (hu) 2008-12-19 2019-08-28 Macrogenics Inc Kovalens diatestek és alkalmazásaik
US8591881B2 (en) 2009-02-05 2013-11-26 Mount Sinai School Of Medicine Chimeric Newcastle disease viruses and uses thereof
CN102361649A (zh) 2009-02-12 2012-02-22 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
EP2413962A1 (de) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Impfstoffe gegen das grippevirus und ihre verwendungen
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
ES2672121T3 (es) 2009-10-07 2018-06-12 Macrogenics, Inc. Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CA2836977A1 (en) * 2010-06-06 2011-12-15 Benjamin R. Tenoever Recombinant rna viruses and uses thereof
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
UA111612C2 (uk) 2011-05-21 2016-05-25 Макродженікс, Інк. Домени, які зв'язуються з деімунізованою сироваткою, і їхнє застосування для збільшення часу напівжиття в сироватці
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
CN104185476A (zh) 2011-09-20 2014-12-03 西奈山医学院 流感病毒疫苗及其应用
US9017694B2 (en) 2011-10-07 2015-04-28 Medimmune, Llc Swine influenza hemagglutinin variants
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
SG10201802982WA (en) 2013-03-14 2018-06-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014284360B9 (en) 2013-07-01 2019-10-24 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
JP6857498B2 (ja) 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための併用方法
AU2015280433B2 (en) 2014-06-17 2020-10-08 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP3218470B1 (de) * 2014-11-13 2022-04-06 Versitech Limited Abgeschwächte lebendimpfstoffe für influenzaviren
WO2016118937A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016222962B2 (en) 2015-02-26 2020-05-21 Boehringer Ingelheim Vetmedica Gmbh Bivalent swine influenza virus vaccine
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2017031408A1 (en) 2015-08-20 2017-02-23 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
WO2017031404A1 (en) 2015-08-20 2017-02-23 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
US10973903B2 (en) 2015-08-20 2021-04-13 University Of Rochester NS1 truncated virus for the development of canine influenza vaccines
US10494613B2 (en) 2015-08-28 2019-12-03 Wisconsin Alumni Research Foundation (Warf) Generation of infectious influenza viruses from virus-like particles
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
JP2019520338A (ja) 2016-06-03 2019-07-18 ユニバーシティ オブ ロチェスター ウマインフルエンザウイルス弱毒生ワクチン
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US11576963B2 (en) 2018-02-27 2023-02-14 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CA3130781A1 (en) 2019-02-27 2020-09-03 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786600A (en) * 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
PT702085E (pt) † 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
DK0780475T4 (da) † 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus
JPH11512609A (ja) † 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産

Also Published As

Publication number Publication date
ATE126272T1 (de) 1995-08-15
DE122007000059I2 (de) 2009-11-05
ES2075901T5 (es) 2007-05-01
DE122008000059I2 (de) 2009-12-31
NL300300I1 (nl) 2008-01-02
DE122007000069I2 (de) 2009-11-12
DE69021575T3 (de) 2007-05-16
AU6411890A (en) 1991-04-08
ES2075901T3 (es) 1995-10-16
US5578473A (en) 1996-11-26
DE122007000069I1 (de) 2008-02-14
DE69021575D1 (de) 1995-09-14
DE69021575T4 (de) 2009-09-10
WO1991003552A1 (en) 1991-03-21
EP0490972A4 (en) 1993-03-31
NL300341I1 (nl) 2008-06-02
US5166057A (en) 1992-11-24
DE122007000059I1 (de) 2007-12-20
AU636916B2 (en) 1993-05-13
CA2065245C (en) 2002-11-12
DE69021575T2 (de) 1995-12-14
DE122008000059I1 (de) 2009-04-09
DK0490972T3 (da) 1995-10-30
EP0490972B1 (de) 1995-08-09
EP0490972A1 (de) 1992-06-24
DE122008000060I1 (de) 2009-02-12
JP3293620B2 (ja) 2002-06-17
NL300367I1 (nl) 2009-01-05
NL300366I1 (nl) 2009-01-05
DE122008000060I2 (de) 2010-12-16
CA2065245A1 (en) 1991-03-01
PT95124A (pt) 1991-04-18
PT95124B (pt) 2001-05-31
GR900100639A (el) 1991-12-30
EP0490972B2 (de) 2006-10-11
JPH05500607A (ja) 1993-02-12

Similar Documents

Publication Publication Date Title
DK0490972T3 (da) Ekspressionssystemer for rekombinante negativstreng-RNA-vira og vacciner
Fodor et al. Rescue of influenza A virus from recombinant DNA
HK1159188A1 (zh) 重組的新城疫病毒 表達系統及疫苗
Garcia-Sastre et al. Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus
EP1035209A1 (de) Stabile rekombinante Influenzaviren, die frei von Helfervirus sind
MX9700817A (es) Secuencia viral de nucleotidos de "vr-2332" y metodos de uso.
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
MXPA02005525A (es) Clones infecciosos.
Beyer et al. Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference
DE60033180D1 (de) Auf dem rinderimmunschwächevirus (biv) basierte vektoren
WO1999057284A3 (en) Attenuated influenza viruses
KR910700347A (ko) 프로모터, 그를 함유하는 플라스미드 및 재조합 아비폭스비루스
CN111471696A (zh) 一种构建d型流感病毒反向遗传操作系统的方法及其应用